Acute Myeloid Leukemia Staging 

Two staging systems are commonly used for acute myeloid leukemia (AML). The French-American-British (FAB) classification system is based on morphology to define specific immunotypes. The World Health Organization (WHO) classification reviews chromosome translocations and evidence of dysplasia. ^[1]

Table. FAB classification of AML (Open Table in a new window)

WHO classification of AML and related neoplasms

AML with recurrent genetic abnormalities ^{[2, 3]} :

• AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
• AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBEB-MYH11
• Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); PML-RARA
• AML with t(9;11)(p22;q23); MLLT3-MLL
• AML with t(6;9)(p23;q34); DEK-NUP214
• AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
• AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1
• Provisional entity: AML with mutated NPM1
• Provisional entity: AML with mutated CEBPA

AML with myelodysplasia-related change

Therapy-related myeloid neoplasms

AML, not otherwise specified:

• Undifferentiated AML (M0)
• AML with minimal differentiation (M1)
• AML without maturation (M2)
• AML with maturation (M2)
• Acute myelomonocytic leukemia (M3)
• Acute monoblastic/monocytic leukemia (M4)
• Acute erythroid leukemia (M5)
• Pure erythroid leukemia (M6)
• Erythroleukemia, erythroid/myeloid (M6)
• Acute megakaryoblastic leukemia (M7)
• Acute basophilic leukemia
• Acute panmyelosis with myelofibrosis

Myeloid sarcoma

Myeloid proliferations related to Down syndrome:

• Transient abnormal myelopoiesis
• Myeloid leukemia associated with Down syndrome

Blastic plasmacytoid dendritic cell neoplasm